Resultados financieros en millones de dólares estadounidenses. El ejercicio fiscal es febrero - enero.
Breakdown
TTM
06/30/2025
06/30/2024
06/30/2023
06/30/2022
06/30/2021
Ingresos
55
55
55
59
72
84
Crecimiento de los Ingresos (YoY)
0%
0%
-7%
-18%
-14%
8%
Costo de los ingresos
25
25
25
26
23
22
Utilidad bruta
29
29
29
33
49
62
Venta, General y Administración
43
39
38
48
46
45
Investigación y Desarrollo
15
15
22
20
15
12
Gastos de Operación
57
57
63
68
61
58
Otras Ingresos (Gastos) No Operativos
--
0
0
0
0
0
Ingreso antes de impuestos
-39
-39
-39
-41
-12
3
Gasto por Impuesto a la Renta
0
0
0
1
1
0
Ingreso Neto
-40
-40
-38
-43
-13
2
Crecimiento de la Utilidad Neta
5%
5%
-12%
231%
-750%
-71%
Acciones en Circulación (Diluidas)
4,766.44
4,766.44
3,743.33
1,456.28
1,396.83
1,469.97
Cambio de Acciones (YoY)
0%
27%
157%
4%
-5%
118%
EPS (Diluido)
0
0
-0.01
-0.02
0
0
Crecimiento de EPS
-21%
-18%
-65%
199%
-595%
-81%
Flujo de efectivo libre
-31
-31
-35
-33
-17
5
Flujo de efectivo libre por acción
--
--
--
--
--
--
Margen bruto
52.72%
52.72%
52.72%
55.93%
68.05%
73.8%
Margen de operación
-49.09%
-50.9%
-61.81%
-57.62%
-16.66%
4.76%
Margen de beneficio
-72.72%
-72.72%
-69.09%
-72.88%
-18.05%
2.38%
Margen de flujo de caja libre
-56.36%
-56.36%
-63.63%
-55.93%
-23.61%
5.95%
EBITDA
-23
-24
-30
-30
-8
8
Margen de EBITDA
-41.81%
-43.63%
-54.54%
-50.84%
-11.11%
9.52%
D&A para EBITDA
4
4
4
4
4
4
EBIT
-27
-28
-34
-34
-12
4
Margen de EBIT
-49.09%
-50.9%
-61.81%
-57.62%
-16.66%
4.76%
Tasa de Impuesto Efectiva
0%
0%
0%
-2.43%
-8.33%
0%
Estadísticas clave
Cierre Anterior
$0.11
Precio de apertura
$0.11
Rango del día
$0.11 - $0.11
Rango de 52 semanas
$0.052 - $0.11
Volumen
15.0K
Volumen promedio
0
EPS (TTM)
-0.01
Rendimiento de dividendos
--
Cap. de mercado
$675.5M
¿Qué es ALLERGY THERAPEUTICS?
Allergy Therapeutics Plc is a biotechnology company, which engages in the Research and Development of allergy treatments. The company is headquartered in Worthing, West Sussex and currently employs 602 full-time employees. The company went IPO on 2004-10-11. The firm is focused on the treatment and diagnosis of allergic disorders, including aluminum free immunotherapies that have the potential to cure disease. The company sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional 10 countries. The company sells both injectable and sublingual (oral) allergen-specific immunotherapies. Its pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. Its therapies are traded under various brand names depending on the market, such as Pollinex Quattro, Polligoid and TA Graser Top. Its commercial products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics and Acarovac Plus. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL, and VLP Peanut.